Al Hufuf And Al Mubarraz

Researchers are evaluating the safety and effectiveness of oral Apabetalone combined with dapagliflozin in adults with type 2 diabetes mellitus (T2DM) who have a history of probable or confirmed COVID-19 infection and continue to experience long-lasting symptoms for at least two months. This open-label, multicenter phase II clinical trial focuses on patients whose symptoms began within three months of COVID-19 onset and cannot be explained by other causes. Participants will take oral Apabetalone 100 mg capsules twice daily with meals for up to 12 weeks while continuing their background dapagliflozin therapy at 10 mg daily. The study includes seven in-person clinic visits where data will be collected to assess the treatment's effects. After screening and eligibility confirmation, participants start the Apabetalone treatment on Day 1 and take the medication at home. During the study, participants will undergo various assessments including symptom evaluation, laboratory tests, and questionnaires to monitor their condition and response to treatment. The primary outcome is the patient acceptable symptom state measured at 90 days. Safety and treatment adherence will be closely monitored throughout the study, which involves regular visits over the treatment period.